VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Brown Discusses Acalabrutinib in CLL

Jennifer Brown, MD, PhD
Published: Monday, Feb 27, 2017



Jennifer Brown MD, PhD, director, Chronic Lymphocytic Leukemia Center, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the novel agent acalabrutinib in the treatment of patients with chronic lymphocytic leukemia (CLL).

While the BTK inhibitor ibrutinib (Imbruvica) has been revolutionary in the management of patients with CLL, novel agents such as acalabrutinib are being developed as a more targeted treatment option.

Acalabrutinib has shown promise in patients with CLL that is difficult to treat. It binds to the same site as ibrutinib, but does not inhibit ITK.

Currently, acalabrutinib is in 2 ongoing, phase III registration trials. Preliminary efficacy results look positive, but the follow-up is about 1 year, Brown says.
 


Jennifer Brown MD, PhD, director, Chronic Lymphocytic Leukemia Center, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the novel agent acalabrutinib in the treatment of patients with chronic lymphocytic leukemia (CLL).

While the BTK inhibitor ibrutinib (Imbruvica) has been revolutionary in the management of patients with CLL, novel agents such as acalabrutinib are being developed as a more targeted treatment option.

Acalabrutinib has shown promise in patients with CLL that is difficult to treat. It binds to the same site as ibrutinib, but does not inhibit ITK.

Currently, acalabrutinib is in 2 ongoing, phase III registration trials. Preliminary efficacy results look positive, but the follow-up is about 1 year, Brown says.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x